- Recent Funding
- Investors
- Kite Pharma
Kite Pharma portfolio
Kite Pharma has 1 portfolio company on record at Recent Funding, with 1 investment in the last 12 months. Its most recent investment on record is Aspen Neuroscience's $115M Series B+ round in November 2025, alongside S32, Revelation Partners, Prebys Ventures and 6 others. That company is in Health and bio.
What Kite Pharma invests in
- Health and bio · 1 · 100%
How Kite Pharma invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 1 100% | $115M |
Share is of the 1 round on Recent Funding that name Kite Pharma. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Kite Pharma portfolio companies
AAspen Neuroscience$115MSeries B+ · Nov 2025
| Company | Round with Kite Pharma | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $115M | $339M | Nov 20, 2025 Series B+ |
Most frequent co-investors
SS321 shared round · last Nov 20, 2025
OOrbiMed1 shared round · last Nov 20, 2025
CCormorant Asset Management1 shared round · last Nov 20, 2025
RRevelation Partners1 shared round · last Nov 20, 2025
FFrazier Life Sciences1 shared round · last Nov 20, 2025
- PPrebys Ventures1 shared round · last Nov 20, 2025
- MMedical Excellence Capital1 shared round · last Nov 20, 2025
LLYFE Capital1 shared round · last Nov 20, 2025
LLifeforce Capital1 shared round · last Nov 20, 2025
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
AAngel Academe1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moDDeepWork Capital1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists Kite Pharma, which is a subset of its real portfolio. API: /api/v1/investors/kite-pharma (get a free API key). More: the most active VC firms and new venture capital funds.